( en | de | ru )

 

Disambiguation of "Müller-Hermelink, Hans-Konrad"

Author of the publication

copydeleteadd this publication to your clipboard
A biological definition of Burkitt's Lymphoma from transcriptional and genomic profiling

, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , and . The New England Journal of Medicine, 354 (23): 2419--2430 (2006)

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed. You can also use the button next to the name to display some publications already assigned to the person.

Hans Konrad Müller-Hermelink

Hans Konrad Müller-Hermelink

Maya Müller-Hermelink

Hans Konrad Müller

Nele Ulrike Müller-Hermelink

 

Other publications of authors with the same name

Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study, , , , , , , , , and 8 other author(s). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 (27): 4548–4554 (2009)Microarray-based genomic profiling reveals novel genomic aberrations in follicular lymphoma which associate with patient survival and gene expression status, , , , , , , , , and 18 other author(s). Genes, chromosomes & cancer, 48 (1): 39–54 (2009)Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial, , , , , , , , , and 10 other author(s). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 (23): 3495–3502 (2007)Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease, , , , , , , , , and 2 other author(s). The New England journal of medicine, 348 (24): 2386–2395 (2003)A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling, , , , , , , , , and 25 other author(s). The New England journal of medicine, 354 (23): 2419–2430 (2006)Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL, , , , , , , , , and 12 other author(s). Blood, 116 (23): 4916–4925 (2010)Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials, , , , , , , , , and 10 other author(s). Haematologica, 94 (11): 1569–1580 (2009)A biological definition of Burkitt's Lymphoma from transcriptional and genomic profiling, , , , , , , , , and 25 other author(s). The New England Journal of Medicine, 354 (23): 2419--2430 (2006)